- Previous Close
1.4500 - Open
1.4500 - Bid 1.3600 x 200
- Ask 1.4300 x 200
- Day's Range
1.3800 - 1.4500 - 52 Week Range
1.2200 - 1.9400 - Volume
82,481 - Avg. Volume
242,672 - Market Cap (intraday)
67.079M - Beta (5Y Monthly) 0.48
- PE Ratio (TTM)
-- - EPS (TTM)
-1.2300 - Earnings Date Mar 10, 2025 - Mar 14, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
3.00
Ikena Oncology, Inc. operates as an oncology company that develops differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the United States. Its lead program is IK-930, an internally discovered, oral, TEAD1-selective, small molecule inhibitor of the Hippo pathway. The company also develops IK-595, a molecular glue designed to trap MEK and RAF in an inactive complex. Ikena Oncology, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
ikenaoncology.comRecent News: IKNA
View MorePerformance Overview: IKNA
Trailing total returns as of 2/21/2025, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: IKNA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: IKNA
View MoreValuation Measures
Market Cap
67.08M
Enterprise Value
-62.56M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
101.59
Price/Book (mrq)
0.50
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-22.06%
Return on Equity (ttm)
-37.08%
Revenue (ttm)
659k
Net Income Avi to Common (ttm)
-59.6M
Diluted EPS (ttm)
-1.2300
Balance Sheet and Cash Flow
Total Cash (mrq)
138.03M
Total Debt/Equity (mrq)
6.25%
Levered Free Cash Flow (ttm)
-43.97M